Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02230267 · ClinicalTrials.gov registry record · Phase 2

High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease

A Phase 2 study of Parkinson's Disease, sponsored by University of Nevada, Las Vegas.

Completed
Registry status
Phase 2
Development phase
27
Enrollment target
1
Study location

NCT02230267 is a Phase 2 study of Parkinson's Disease that has completed, run by University of Nevada, Las Vegas. The registered enrollment target is 27 participants, below the 639-participant average among 157 other Parkinson's Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02230267, a Phase 2 study of Parkinson's Disease, has completed, sponsored by University of Nevada, Las Vegas.

COMPLETED
Registry status
Phase 2
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

Several animal and human epidemiologic studies have provided evidence that exercise may be neuroprotective in Parkinson's disease (PD). Exercise may forestall diagnosis and, in the case of those who have already been diagnosed with PD, it may slow the observed neurodegeneration. Unfortunately, because this line of research is in early stages, there is little evidence to indicate what biological mechanisms underlie the neuroprotection that is conferred with exercise. Toward this end, it is possible that an interaction between endogenous antioxidant enzymes, inflammatory processes, and reactive oxygen species may be associated with exercise improvements in PD. One of the most common reasons for premature death in PD is falls. Several meta-analyses have concluded that exercise training programs focused on balance and/or strength training are effective at improving aspects of balance. Taken together, the current body of evidence suggests that exercise may be neuroprotective and balance/strength training may decrease the likelihood of a fall. The combination of these efficacious treatment modalities (exercise and balance/strength training) in a comprehensive treatment approach to improve PD symptoms and balance has been previously reported at relatively mild or moderate exercise intensities. Because recent research has suggested that patients with PD may benefit more from more physically intense programs, we are proposing a more aggressive approach with regard to exercise intensity and frequency in the present trial. The primary purpose of this study is to determine the feasibility and safety of a high intensity exercise approach to PD. A secondary purpose is to determine the trajectory of change in outcomes over the duration of the trial from a high intensity fall prevention program. It is hoped that a signal of efficacy will allow this trial to progress to a comparative effectiveness trial. An important innovative design element is collecting biological assays to bett

Conditions Studied

Interventions

  • OTHER High intensity exercise and balance training
  • OTHER Usual care arm exercise

Study Locations (1)

Nevada

  • University of Nevada, Las Vegas - Las Vegas

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2014-08
Est. Completion 2015-12
Phase Phase 2

Sponsor

University of Nevada, Las Vegas

52 total trials

What the Registry Record Tells You About NCT02230267

The ClinicalTrials.gov registry entry for NCT02230267 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 639-participant average among 157 other Parkinson's Disease trials with a reported enrollment target (96% lower). The listed sponsor is University of Nevada, Las Vegas, which has 52 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which High intensity exercise and balance training is the first listed.

NCT02230267 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.

Frequently Asked Questions

What is clinical trial NCT02230267 about?

NCT02230267 is a clinical study titled "High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease". Several animal and human epidemiologic studies have provided evidence that exercise may be neuroprotective in Parkinson's disease (PD). Exercise may forestall diagnosis and, in the case of those who have already been diagnosed with PD, it may slow the observed neurodegeneration. Unfortunately, becau...

What is the current status of trial NCT02230267?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2014-08. Estimated completion is 2015-12.

What conditions does trial NCT02230267 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT02230267?

The interventions under investigation include: High intensity exercise and balance training (OTHER), Usual care arm exercise (OTHER).

Who is sponsoring clinical trial NCT02230267?

This trial is sponsored by University of Nevada, Las Vegas, which has 52 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02230267 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.